Modified-release tacrolimus

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 270-275

  Chisholm, Marie A ^a,b   Middleton, Matthew D ^c  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Calcineurin inhibitor; Immunosuppressant; MR 4; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MR 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TSUKUBAENOLIDE;

BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MODIFIED RELEASE FORMULATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MEDLINE; TACROLIMUS;

EID: 33144489178     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E657     Document Type: Review

References (17)

1. Gaston RS, Hudson SL, Ward M, Jones P, Macon R. Late renal allograft loss: noncompliance masquerading as chronic rejection. Transplant Proc 1999;31(4A):21S-3S.
2. DeGeest S, Borgermans L, Gemoets H, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995;59:340-7.
3. Didlake RH, Dreyfus K, Kerman RH, Van Buren CT, Kahan BD. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 1988;20(3 suppl 3):63-9.
4. Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Impact of clinical pharmacy services on renal transplant patients' compliance with immunosuppressive medications. Clin Transplant 2001;15:330-6.
5. Chapman JR. Compliance: the patient, the doctor, and the medication? Transplantation 2004;77:782-6.
6. Kardas P. On behalf of the COMPASS Investigators. Comparison of once daily versus twice daily oral nitrates in stable angina pectoris. Am J Cardiol 2004;94:213-6.
7. Package insert. Prograf (tacrolimus). Deerfield, IL: Fujisawa Healthcare, July 2001.
8. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook-pocket. Hudson, OH: Lexi-Comp, 2003.
9. First MR, Fitzsimmons WE. New drugs to improve transplant outcomes. Transplantation 2004;77(suppl):S88-92.
10. Data on file. Company reports 00-0-076, 00-0-077, and 00-0-078. Deerfield, IL: Fujisawa Healthcare, 2001.
11. Data on file. Company reports FG-506-04-21 and FG-506-04-25. Deerfield, IL: Fujisawa Healthcare, 2001.
12. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products-general consideration. BP revision 1. Rockville, MD: Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research, 2003.
13. Alloway R, for the Tacrolimus Modified Release Kidney Conversion Study Group. Conversion of stable kidney transplant recipients from a twice daily Prograf based regimen to a once daily modified release tacrolimus based regimen (abstract 262). Am J Transplant 2004;4(suppl 8):230.
14. Florman S, for the Tacrolimus Modified Release Liver Conversion Study Group. Conversion of stable liver transplant recipients from a twice daily Prograf based regimen to a once daily modified release tacrolimus based regimen (abstract 401). Am J Transplant 2004;4(suppl 8):268.
15. Undre NA, for the Tacrolimus Modified Release Liver Conversion Study Group. Use of once daily modified release tacrolimus regimen in de novo liver transplant recipients (abstract 859). Am J Transplant 2005;5(suppl 11):374.
16. Alloway R, for the Tacrolimus Modified Release Stable Liver Conversion Study Group. A one year follow-up study of stable liver transplant recipients converted from twice daily Prograf (abstract 932). Am J Transplant 2005;5(suppl 11):393.
17. Heffron TG, for the Tacrolimus Modified Release Liver Conversion Study Group. Conversion of stable pediatric liver transplant recipients from twice daily Prograf to once daily modified release tacrolimus (abstract 1394). Am J Transplant 2005;5(suppl 11):511.